
Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a…

Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a…
Stage: Clinical-stage biotech
Therapeutic focus: Allogeneic, off-the-shelf proteomic-driven immunotherapy for solid tumors (lead: STC-1010)
Lead location: Issoire, Auvergne, France
Recent financing: Series A (~€22.2M–$25M reported)
Team size: ~23 employees
Prevention of cancer recurrence / immunotherapy for solid tumors
Biotechnology
Reported ~€22.2M (Dealroom) / $25M (media / Crunchbase)
Multiple institutional investors reported (Crunchbase lists ~11, including Meusinvest)
“Angelor reported as lead investor; multiple institutional investors reported”
R&D SCIENTIST – IMMUNO-ONCOLOGY
• Location: Lyon, France • Start: April 2026 • Contract: Full‑time / CDI
About Brenus Pharma
Brenus Pharma is a French clinical-stage biotech company pioneering next-generation in vivo immunotherapies.
Based in Lyon with a team of 18 people, we're tackling one of oncology's greatest challenges: cold, immune-invisible solid tumors responsible for 90% of treatment failures and nearly 10 million deaths worldwide each year.
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
66,000+
Open Roles
1,300+
New This Week
| Company |
|---|
Our Approach
We are focusing on overcoming cancer resistance and relapse with a unique, patented technology platform Stimulated Tumor Ghost Cell (SGC).
This antigen-based approach mimics cancer biology and educates the patient’s immune system to recognize and eliminate malignant cells.
Clinical progress & momentum
Our lead candidate, STC-1010, targets microsatellite-stable (MSS) colorectal cancer to address a major unmet medical need for patients whose current treatment options remain limited to chemotherapy. The program entered Phase I/IIa clinical trials in July 2025.
Backed by €23M in Series A funding (2024) from leading European investors, and supported by BPIFrance, Région Auvergne Industrie, and France 2030, Brenus Pharma aims to become a major player in immuno-oncology, driven by breakthrough innovation with meaningful patient impact.
Role Overview
We are looking for a motivated R&D Scientist in immuno-oncology to support and steer research programs conducted mainly through external partners.
You will provide scientific oversight, deliver high-quality data interpretation, and contribute to mechanism of action and translational activities that inform decisions across the pipeline.
You’ll thrive in this role if you enjoy turning complex datasets into clear insights, collaborating closely with partners, and shaping follow‑up experiments that move programs forward.
What You Will Do
What You Bring
Must‑Have
Nice‑to‑Have
Education & Experience
Culture & Values: Equity, Transparency, Perseverance
By joining the team, you’re stepping into a company where science, people and purpose all move forward together.
At Brenus, our culture is built around curiosity, learning and the constant desire to grow, individually and collectively. We value creativity, open-mindedness, teamwork and the joy of sharing moments together, whether it’s ideas, challenges, or new experiences.
As a team, we’re supportive, adaptable and engaged. Collaboration, mutual help and the ability to find solutions together are at the heart of our daily work.
Beyond our projects, we are driven by something bigger: contributing to a positive impact on the world, especially in the field of healthcare. Pushing scientific innovation, improving patients’ lives and building a fairer, more sustainable future guides our mission.
To apply, please email your CV to irichert@brenus-pharma.com, along with a brief statement describing your motivation for the position.